OrbiMed’s Artivion AORT Stock Holding History

OrbiMed’s Portfolio AORT Stock Details AORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.93M	Buy	175,000 +24,000	+16%	+$671K	0.07%	109
2026 Q1	$5.53M	Buy	+151,000	New	+$5.96M	0.11%	92

Other funds holding AORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JIC

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

OrbiMed's AORT Position: Q2 2026 in Review

OrbiMed increased its Artivion (AORT) stake by 16% in Q2 2026, buying an estimated $671K and bringing the position to 175,000 shares worth $3.93M. The position accounts for 0.07% of the portfolio, ranked #109.

OrbiMed first reported a position in AORT in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.53M in Q1 2026. 206 funds tracked by Wall St. Rank hold AORT as of Q2 2026.

OrbiMed held 175,000 shares of Artivion worth $3.93M as of Q2 2026.
OrbiMed bought 24,000 Artivion shares in Q2 2026, an estimated $671K.
Artivion made up 0.07% of OrbiMed's portfolio in Q2 2026, its #109 holding.
OrbiMed first reported a position in Artivion in Q1 2026 and has held it in 2 quarters since.
OrbiMed's Artivion position peaked at $5.53M in Q1 2026.
206 funds tracked by Wall St. Rank held Artivion as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.